GU Cancer Clinical Trials

UCI 16-19 ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy (Uchio)

*SUSPENDED* UCI 16-76 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) (Mar)

UCI 17-10 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/ Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/ Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer (Mar)

UCI 17-25** A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/ Prednisone) (Uchio)

UCI 17-41** A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (Uchio)

UCI 17-86 Phase 1 Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy (Ahlering)

UCI 18-47* A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Deficiencies (TALAPRO-2) (Uchio)

**Opening soon

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

Version 07/18
**GU Cancer Clinical Trials**

**UCI 17-40** Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response (Uchio)

**Observational**

**UCI 00-55** Retrospective Evaluation of Prostate Cancer Clinical and Pathological Outcomes (Ahlering)

**Screening & Correlative**

**PROSTATE CANCER**

**Epidemiologic**

**UCI 14-90** Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading (Mercola)

**Prevention**

**UCI 98-41** Outcomes and Assessment of Prostate Cancer at UCIMC (Ahlering)

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

---

**UCI 13-03** Office-Based Percutaneous Ultrasound-Guided Renal Biopsy (Landman)

**UCI 11-19** Evaluation of Peritumoral Renal Adipose Tissue to Renal Cancer Aggressiveness (Landman)

**UCI 16-57** Phase-I trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas (Landman)

**UCI 16-84** A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti–PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy (Uchio)

---

**RENAL CANCER**

- **Epidemiologic**
- **Screening**
- **Treatment**
**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**Version 07/18**
For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**Opening soon**